Acutely psychotic schizophrenic patients not taking tmtipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HV A) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid ((SF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HV A levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HV A correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well. [Neuropsychopharmacology 8:97-109, 1993J by the receptor blockade (Carlsson and Lindqvist 1963) .
increased in all three fluids. There were many significant correlations between plasma MHPG and HV A levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HV A correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well. [Neuropsychopharmacology 8:97-109, 1993J by the receptor blockade (Carlsson and Lindqvist 1963) .
In the aggregate, these initial and subsequent basic neu ropsychopharmacologic studies have led to the ''DA hy pothesis of schizophrenia or psychosis," which suggests that schizophrenia/psychosis is associated with either an increase in central nervous system (CNS) DA release or an increase in DA receptor sensitivity (for recent reviews see Davis et al. 1991; Seeman et al. 1987) . Sub brains of schizophrenics has its problems and therefore, attention has also focused on the simpler approach of studying relationships between the DA metabolite, plasma homovanillic acid (HV A), and schizophrenic! psychotic symptoms. Bowers et a1. (1984) , in a study of a diagnostically mixed group of psychotics, found that patients who had good outcomes with haloperidol treatment had signifIcantly higher pretreatment plasma HV A concentrations than did those patients with poor outcomes. Further, the plasma HV A values in the good outcome group signifIcantly decreased after 3 weeks of drug treatment whereas the poor outcome group's values were unchanged. This fInding was replicated by Davila et al. in 1988. In studies of schizophrenic patients Pickar et a1. (1984 Pickar et a1. ( , 1986 found that neuroleptic treat ment was associated with a time-dependent decrease in plasma HV A values over a 5-week period and that this decrease was correlated with changes in psychosis ratings. Apparently all of the patients showed some de gree of improvement, and it is thus difficult to know whether the plasma HV A decrease was associated with symptom change, per se, or represented a pharmaco logic adaptation or "tolerance" to the neuroleptic. This issue is of interest because it has been reported that the development of tolerance, as assessed by changes in CSF HV A is associated with a favorable treatment out come (Bowers et a1. 1984) . Davis et a1. (1985) , Muscet tola et al. (1990) and Davidson et al. (1991a,b) have found signifIcant relationships between the severity of sym ptomatology in psychotic schizophrenics and concen trations of plasma HV A. Failure to fInd this association has also recently been reported (Javaid et al. 1990 ).
Although these studies of plasma HV A in schizo phrenia and psychosis are most interesting and sug gest empirical leads, a potential problem of interpreta tion arises. Homovanillic acid is formed both in the periphery and in the brain, with estimates indicating that of the total-body HV A formed, about 11 % to 35%, arises in brain (Bacopoulos et a1. 1978 (Bacopoulos et a1. , 1979 Elsworth et a1. 1982; Maas et a1. 1977 Maas et a1. , 1979b Maas et a1. , 1988 Elchisak et a1. 1979; Anggard et a1. 1974; Kopin et al. 1988; Lam bert et a1. 1991) . The problem of the peripheral produc tion of HV A for the interpretation of results of studies with psychotic patients is particularly troublesome be cause plasma levels of DA can be increased by activity and changes in peripheral sympathetic nervous system activity as well as by stress and agonist challenges (Snider and Kuche1 1983; Van Loon et al. 1979a,b; Buh ler et al. 1978) . Measurements of concentrations of plasma metabolites may not give a measure of rates of synthesis or metabolism because the plasma concen tration of any substance may change as a function of clearance rates (Potter et al. 1989) , metabolic shunts, changes in extracellular fluid volume, rhythm of excre tions, and the route of disposition of the metabolite.
If one assumes that all of the metabolite is excreted in NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 urine, as appears to be the case with HV A (Miller et al. 1987) , assays of total metabolite present in urine may give a better measure of the rate of synthesiS or metab olism of the substance under scrutiny than plasma con· centrations.
Following an initial report by Karoum et a1. (1974) , our group and others have used debrisoquin (DBQ) as a research tool, for it appears to create a condition in which the peripheral measurement of HV A or 3-meth· oxy-4-hydroxyphenylglycol (MHPG) in plasma or urine better reflects respectively DA and perhaps norepineph rine (NE) system function within the CNS (Maas et ai, 1979a (Maas et ai, , 1980 (Maas et ai, , 1988 Swann et al. 1980; Kopin et al. 1983 Kopin et al. , 1988 Riddle et al. 1986 and unpublished observations) .
Debrisoquin is an antihypertensive drug having guan ethidine-like properties, which inhibits monoamine ox idase (MAO) and does not enter brain (Medina et aI. 1969; Kitchin and Turner 1966; Tomlinson and Mayor 1973) . Given these properties, it was hypothesized that administration of DBQ would produce a decrease in production of HV A and MHPG in the periphery but not in the brain, thereby amplifying the relationships between central production of and peripheral measures of HV A and/or MHPG. Previous work with human sub jects and subhuman primates has in part confIrmed this hypothesis (Maas et a1. 1988 (Maas et a1. , 1979a Swann et a1. 1980; Riddle et a1. 1986 and unpublished observations) . Be fore administration of DBQ in subhuman primates there was no signifIcant correlation between plasma HV A and the brain's production of this metabolite. During DBQ administration the brain's output of HV A was un changed but plasma HV A concentrations were de creased and there was a modest positive correlation (r = .55, P < .05, n = 16) between plasma HVA levels and the brain's production of HV A (Maas et a1. 1979b and unpublished observations).
A review of DA system function in schizophre nia/psychosis illustrates that the dose Ki for neurolep tic drugs and the clinical dosage needed for therapeu tic response are closely related and this is consistent with a role of DA in schizophrenia/psychosis. However, a variety of human clinical studies of the "DA hypoth.
esis" have yielded more controversial or generally nega tive fIndings (Bunney 1978; Hornykiewicz 1978; Melt zer and Stahl 1976; Bowers 1980; van Kammen 1977; van Praag 1977; Haracz 1982; Gershon et a1. 1967; Nas rallah et al. 1977; Persson and Roos 1969; Bowers et aI. 1969; Rimon et al. 1971; Berger et a1. 1980) . In contrast to DA, a role for altered NE system func tion in schizophrenia is more strongly supported by hu man studies than by animal investigations. For exam ple, there are studies involving brain autopsy material to indicate that NE is increased in the nucleus accum bens (Farley et al. 1978) , particularly in paranoid schizophrenics (Farley et al. 1980) . Also, Ko et al. (1988) and Joseph et al. (1976) (Gomes et al. 1980; KemaH et al. 1982; Stern berg et al. 1981; van Kammen et al. 1990 ). Breier et al. (1990) found that plasma NE levels correlated with both positive and negative symptoms of schizophrenia. Sternberg et al. (1982) and van Kammen and Antelman (1984) found that acute administration of the u2-adren ergic agonist clonidine did not produce the same quan titative decrease of plasma MHPG that was seen in con trol and depressed subjects. They speculated that U2 presynaptic receptors modulating NE release may be less sensitive in schizophrenic patients. Data have been reported that support this hypothesis for a subgroup, but not all patients (Glazer et al. 1987) . Van Kamm en et al. (1989) reported that clonidine was possibly therapeu tic for paranoid schizophrenics but not for other types of schizophrenics, whereas Freedman et al. (1982) found that clonidine was as effective as haloperidol for the treatment of schizophrenia! psychosis in patients who have previously responded well to neuroleptics.
In this paper we report signifIcant differences be tween con trol and patient concentrations of MHPG and HV A in plasma, and of urinary output of MHPG (but not of urinary output of HV A). These differences were most co nsistently found during DBQ administration and the y generally agree with other reports using the same paradigm but without the use of DBQ. We also note signifIcant relationships between plasma MHPG concentrations and symptom severity (including nega tive symptoms), but not between negative symptoms and plasma HV A values, and develop the hypothesis that alterations in brain NE system function may be in volved with both negative and positive symptoms and alterations in brain DA systems only with positive symptoms.
MATERIALS AND METHODS

Subjects
Patients included in this study were 25 men between the ages of 21 and 65 years who met research diagnos tic criteria (ROC) (Spitzer et al. 1978 ) for schizophre nia. All patients were acutely ill and sufficiently symp tomatic so that hospitalization was medically indicated. In several instances the recurrence of symptoms devel oped after patients had stopped taking neuroleptic medication. Patients receiving depot neuroleptics were not admitted to the study if the injection had been done Catecholamine Metabolism in Schizophrenia 99 within the preceding 2 months. Subjects were main tained without psychotropic drugs for 2 weeks after ad mission to the hospital. Occasional chloral hydrate was given for agitation. All patients were free of major med ical illnesses and voluntarily agreed to participate after receiving a full explanation of the nature of the study.
Two patients had no previous psychiatric hospital ad missions but the others had had multiple admi�sions.
Subjects were hospitalized on a psychiatric clinical re search unit of the Audie L. Murphy Memorial Veter ans' Hospital (ALMMVH), in San Antonio, Texas.
Subjects were maintained on a low-tyramine, low vanillymandelic acid diet and restricted from using al cohol and caffeine throughout the study. The study was approved by the Institutional Review Board.
Control subjects were a group of 10 males having the same age distribution as the patient group. These control subjects were free of diagnosable psychopathol ogy using ROC as determined by two psychiatrists (J. W.M. and E.S.). Control subjects were also hospital ized at the ALMMVH on a clinical research unit and were subject to the same dietary restrictions as the pa tients. The timing and procedures for body fluid col lections were similar to those for patients.
Study Design
On the 7th or 3rd day after admission to the hospital (patients and control subjects respectively) the subjects had blood samples drawn at 8:00 A.M. and 10:00 A.M. This is referred to as "off DBQ" baseline day 1. For those patients who consented on this "off DBQ" baseline day, a lumbar puncture was performed at 9:00 A.M., with the patient in the sitting position. A total of 14 ml of CSF was removed from each patient, with the initial 2 ml of CSF being used for clinical chemistry studies and the remaining 12 ml for the determination of HV A and MHPG concentrations. Control subjects did not have this lumbar puncture performed on this " off DBQ" base line day. On the same day, 3. 5-hour urine collections were obtained from patients and control subjects as fol lows. Subjects received nothing orally, except for wa ter ad libitum, from midnight until the completion of the urine collection. Patients were kept at bedrest and were under a research nurse's observation the entire time. Urine was collected from 8:30 A.M. until noon.
This methodology allowed us to control for diet and activity (Kendler et al. 1983) , as well as assuring com pleteness of collection.
After these "off DBQ" samples had been obtained, subjects began receiving DBQ at a dosage of 10 mg twice daily for the 1st day and 10 mg four times daily there after. For the initial phases of this study patients re ceived DBQ for 14 days before the second collection of biologic specimens, but subsequently this time was re duced to 7 days once it had been established that the decrements in plasma HV A associated with DBQ ad ministration were equal at 7 and 14 days (Maas et al. 1985) . Three subjects received DBQ for 14 days and the rest for 7 days. No effect of the additional time on DBQ in metabolite levels assayed was seen when compari son was done with "runs" tests. Patients receiving DBQ for 7 or 14 days were pooled for this study. All control subjects received DBQ for 7 days. After 7 (n = 20) or 14 days (n = 3) of DBQ treatment, blood was again drawn at 8 A.M. and 10 A.M. and 3. 5-hour urine speci mens were obtained. This second blood drawing and urine collection are referred to as the "on DBQ" base line. For consenting patients and control subjects, a lumbar puncture was performed on this " on DBQ" base line day.
While taking DBQ, patients and control subjects were given challenge tests with placebo, apomorphine, and haloperidol as follows. On the 1st day subjects were given either placebo or apomorphine on a randomized double-blind basis. On the 2nd day they received whichever drug (apomorphine or placebo) they had not received on the 1st day. On the 3rd challenge day they were given haloperidol intramuscularly (0. 2 mg/kg). It should be noted that the results of the placebo or apomorphine were the same (no effect) and the order of the type of drug was without effect (half-life of apomorphine is relatively short). The full results of these challenge tests will be reported elsewhere, but for this paper, the effects of the placebo challenge are presented to illustrate the time course of changes of HV A concen tration in plasma.
Immediately after urine, plasma, and CSF collec tion, sodium metabisulftte (50 mg/ml) and deuterated standards were added to the specimens. Urine speci mens were assayed for creatinine (Helger et al. 1974) , and these values along with the nursing observations made during the collection period were used to deter mine completeness of collection.
Analysis Procedures for HV A and DOPAC
For the HV A and dihydroxyphenylacetic acid (DOPAC) analyses of urine, 0. 5 ml of urine was spiked with 0. 5 ml of a combined 10-ng/J.11 4-hydroxy-3-methoxyphenyl acetic-2, 2-d2 acid (d2-HV A) and 3,4-dihydroxyphenyl d3-acetic-2, 2-d2 acid (d5-DOPAC) solution. Aliquots of 2. 5 ml of plasma and CSF were spiked with 250 J.11 of a 1-ng/J.11 d2-HV A, d5-DOPAC solution. After thor ough mixing, specimens were acidifIed with 0.4 ml of hydrochloric acid (1.25 N) per milliliter of sample. Urine specimens were further diluted with 1. 2 ml of distilled deionized water.
Analysis Procedures for MHPG
For MHPG analyses 2.5 ml of CSF or plasma was added to vials containing 500 ng of dry 3-methoxy-4-hydroxy-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 phenylglycol-d3 (d3-MHPG). Urine, 2.5 ml, was added to vials containing 5 J.1g of dry d3-MHPG. All specimens were split into two equal aliquots and frozen at -70°C until time of assay. Plasma, urine, and CSF samples were assayed for HV A, DOPAC, and MHPG using gas chromatography-mass spectroscopy (selected ion mon itoring) methods as previously described (Maas et a1. 1979a ).
Calculation of Clearance Rates
Clearance rates were calculated by the formula Vc/P where V is volume of urine, C is the urine's concentra tion of the substance being studied and P is its plasma or serum concentration. The urine clearance values are expressed as milliliters per minute to allow compari son with values in the literature.
Data Collection Analysis
For independent samples t-tests were used to compare plasma and urinary metabolites between the patients and control subjects during the "off DBQ" and "on DBQ" days. Repeated-measures analysis of variance (ANOV A) was used to determine whether there was a time effect on plasma HV A during the placebo chal lenge day and to determine if there were between group differences in the time effect.
Platelet Assay
Platelet MAO activity was determined by a modifIed version of the method described by Murphy et al. (1976) and used benzylamine as the substrate. For this assay, blood (10 ml) was collected at 8 A.M. in specimen tubes containing acetic acid and kept on ice until centrifuged.
Platelet-rich plasma was pooled two times and again centrifuged to obtain a platelet pellet. The pellet was resuspended in 2 ml of Ringer's-citrate-dextrose buffer (pH, 6.5), split into aliquots, and frozen at -70°C until the time of assay. 
Psychometric Measurements
During the fIrst 7 days in the hospital, all patients underwent structured interviews during which the 
Patients
6.6 ± 3.1 5.9 ± 2.4 374.7 ± 140.4 49.2 ± 30.6 (n = 25) (n = 25) (n = 13) (n = 13) P � 0.002 P � 0.0002
3.5 ± 0.9 314.8 ± 67.9 28.3 ± 17.9 (n = 10) (n = 9) (n = 10) (n = 10)
Values for (SF and plasma are expressed as nanograms per milliliter ± SD and for urine as total �g/3.5 hours ± SD. The number of subjects is given in parentheses and the signifIcance of differences between patients and controls as p values.
Schedule for Affective Disorders and Schizophrenia (SADS)-Lifetime Version was completed. After this the SADS-Change Version (SADS-C) and SADS-C Global Assessment Scale (GAS) (Spitzer and Endicott 1979) were obtained on the 7th day of hospitalization as well as after 7 or 14 days of DBQ treatment. On these same days the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) was administered by one of us (S.A.c.). We also used items (#3,7,13,16) from the BPRS to quantitate negative symptoms as detailed by Thie mann et al. (1987) . Thought disorder subscales from the BPRS, SADS, and a psychosis subscale from the Nurs ing Evaluation Scale (NES) were chosen to quantify psy choticism. The SADS-C GAS and BPRS were also used to measure overall illness severity. The thought disor der subfactor was obtained from the SADS-C scale using the sum of ratings on items 148 (severity of delu si ons), 149 (severity of hallucinations), 157 (impaired understanding), 160 (bizarre behavior), and 158 (inap prop riate affect). From the NES, which is a modifIca tion of the Nurses' Observation Scale for Inpatient Eval- . Correlations between plasma measures of metabolite and behavior were made by taking the mean morning values of metabolite mea sures before and after 7 days of DBQ treatment and looking at their relationship to the behavioral rating on the same day.
RESULTS
We compared hospitalized patients and healthy con trol subjects, using data from the "on" and "off" DBQ days.
The results for urine, plasma, and CSF analyses of HV A for patients and control subjects are shown in Ta ble 1. During the "off DBQ" condition plasma HV A con centrations in schizophrenics exceeded those of con trol subjects on one but not the other time of blood sampling. Urine values of HV A for the patients and con trols did not differ at this time. During DBQ adminis tration these differences in plasma HV A between pa tients and control subjects were more clearly evident, but, as before, urine HV A values for the two groups did not differ between patients and controls.
This disparity between urinary and plasma HV A levels could have occurred because plasma levels of HV A changed as a function of a variety of factors in cluding renal clearance (Potter et al. 1989) . However, as shown in Table 2 there were no signifIcant diff erences in HV A clearance between groups nor was there a signifIcant effect on renal clearance of DBQ. The calcu- (n = 24) (n = 24) (n = 12) (n = 13) P = NS P = NS P = NS P = NS Controls 1.3 ± 1.7 0.7 ± 0.4 66.7 ± 17.2 8.6 ± 6.6 (n = 10) (n = 8) (n = 10) (n = 10)
Values for CSF and plasma are expressed as nanograms per milliliter ± SO and forurine as total �g/3.5 hours ± SO. The number of subjects is given in parentheses and the signifIcance of differences between patients and controls as p values.
lations for clearance of HV A by patients and control sub jects were done on a subset of patients (those with both plasma and urinary values for HVA). The disparity be tween plasma and urinary HV A comparisons was also noted in the subset.
Plasma concentrations of metabolites may also differ secondary to metabolic shunts (or alack thereof). We therefore assayed another metabolite of DA, DOPAC, in plasma and urine. As may be seen in Table  3 there were no signifIcant differences in DOPAC be tween patients and controls in plasma, urine, or CSF. The differences between patients and control subjects in plasma HV A, but not urinary HV A, may have oc curred because the system was not at a steady state and/or the diurnal rhythms for patients and control sub jects were markedly different. We therefore looked at changes in plasma HV A over a 3-hour period in both patients and controls while both groups were receiv ing DBQ. The results are shown in Figure 1 . An ANOV A with repeated measures indicated a strong time effect for both patients (p < .0001) and control sub jects (p < .0001), and that overall patients had signifI cantly greater plasma HV A concentrations than con trol subjects (p = .0007), but there were no differences in the patterns of the plasma HV A rhythm seen in pa tients versus controls. There were no diagnosis x time interactions. Thus, the difference found for plt�ma HV A between patients and controls but not for urinary HV A is not thought to be a function of the difference in time course of plasma HV A levels between the two groups.
The results for plasma, urine, and CSF MHPG are shown in Table 4 . During the "off DBQ" period the uri nary values of MHPG were signifIcantly higher in patients than in controls, but plasma levels were not. Af ter DBQ administration both plasma and urinary values for MHPG were higher in patients as compared to con trol subjects.
In contrast to HV A, MHPG can be further me tabolized to vanillylmandelic acid (VMA) and/or its conjugates. We also measured free MHPG in plasma, as well as total (free and conjugated) MHPG in urine, Time (min) Figure 1 . Plasma HV A (ng/rnl) in patients and control sub jects following subcutaneous injection of placebo. All patients and control subjects were on DBQ for at least 7 days and off neuroleptics for at least 14 days. (n = 23) (n = 23) (n = 8) (n = 13) P � .001 P � .002 P � 0.002 P � 0.01 Controls 0.8 ± 0.2 0.9 ± 0.2 59.4 ± 25.9 2.9 ± 0.8
Values for CSF and plasma are expressed as nanograms per milliliter ± SD and for urine as total �g/3.5 hours ± SD. The number of subjects is given in parentheses and the significance of differences beween patients and controls as p values.
where it is approximately 95% conjugated. Therefore clearance rates could not be calculated for MHPG.
Because of the possible relationships between the functioning of DA and NE systems (Antelman and Cag giula 1977; Grenhoff and Svensson, 1989) , we con structed ratios of MHPG to HV A for all patients and control subjects and then compared this ratio between the schizophrenic and control subjects. We also cor related these ratio values with the behavioral variables. No signiftcant differences or relationships were found except for the expected difference between patients and control subjects for the urinary MHPG/HV A ratio.
That the fmding of an increase in urinary and plasma MHPG or the increase in plasma HV A in pa tients is not an artifact of greater MAO inhibition in con trol subjects is suggested by the data (Table 5) , which indicate that the degree of MAO inhibition in platelets Values are means ± SD. The number of patients or controls is given in parentheses. Differences between patients and controls on or off DBQ are not significant, nor is the decrement in MAO associ ated with DBQ administration significantly different between pa tients and controls. However the absolute change in MAO activity assoc iated with DBQ administration is highly significant (p < 0.006) for both patients and controls, respectively.
is not significantly different for patients and controls receiving DBQ. Patient and control groups were matched for gender and had similar age distributions. Height was not signifIcantly different between the patients and controls. Although the patients were signifIcantly heavier, no significant relationships be tween body weight and any of the metabolite values in any of the body fluids examined were found. Creati nine values for the 3.5-hour urine samples were not signifIcantly different across days, suggesting that the collections were complete (data not shown).
We examined interrelationships between behavioral measures and plasma concentrations of HV A and MHPG before and during DBQ administration. Results with HVA have been previously reported (Maas et al. 1988) . In brief, plasma HV A was signifIcantly correlated (p < .01) with the SADS-C GAS, the SADS-C Thought Disorder Factor, the total BPRS score, and the psycho sis subscale of the NES during, but not before, DBQ administration. In the present study ( Table 6 ) we found that plasma MHPG was positively correlated with posi tive symptoms of schizophrenia, but not with anxiety or aggression. Plasma MHPG was also positively cor related with the negative symptom score as measured with the BPRS (r = 0.68, n = 15, P < .01). These rela tionships were generally stronger for patients on DBQ than off DBQ. In contrast to plasma MHPG, the corre lation between negative symptoms and plasma HV A on DBQ was not significant (r = .204, n = 15, P = .448). Because of a very weak trend toward a correlation be tween the BPRS disturbed thought and negative symp toms subscales (r = .344, n = 15), a partial correlation coeffIcient between negative symptoms (BPRS) and plasma MHPG was computed taking into account this latter relationship. This corrected correlation coefficient was r = .66, n = 15, P < .01.
DISCUSSION
The major fIndings of this work may be summarized as follows. In the comparison between acutely psychotic schizophrenic patients and control subjects, plasma MHPG and HV A levels were increased, CSF levels of MHPG but not of HV A were increased, and urinary output of MHPG but not of HV A was increased. Corre lations of clinical measures of thought disorder and psy chotic behavior with plasma levels of MHPG and HV A were robust. All of these fIndings were stronger when patients and control subjects were treated with DBQ. We hypothesize that this may be because with DBQ it is possible to obtain a clearer picture of CNS events. However, it is also true that DBQ may produce a reduc tion in the group variance of metabolite values by other unspecified mechanisms and this may make statistical comparisons sharper. This is not to say that differences between patients and controls cannot be found with out DBQ, because many other groups have reported NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 such differences. The fact that differences in HV A and MHPG emerge more clearly with DBQ treatment does suggest that diff erences in concentrations of neurotrans mitter metabolites found without DBQ are more likel y attributable to changes in CNS rather than peripheral neurotransmission. This discussion will focus on: 1) the evidence for disturbed NE metabolism in schizophre nia; 2) the possible interpretations of the apparent discrepancy between altered plasma HV A without changes in urine and CSF HV A; and 3) exploration of NE-DA interactions as they may relate to the fIndings in this study.
Our fIndings of positive and signifIcant relation· ships between plasma MHPG and both positive and negative symptoms are in general agreement with noradrenergic changes that have been hypothesized or reported by others (Bowers et a1. 1984; Ko et a1. 1988; van Kammen et a1. 1990; Stein and Wise 1971) . The faet that our most robust findings were found when sub jects were receiving DBQ does strengthen the likelihood that the fIndings can be related specifIcally to events in brain. The fInding of an increase in MHPG in the pa· tient group in urine and plasma is consistent with the hypothesis (Sternberg et al. 1982 ) that there are sub sensitive (12 presynaptic adrenergic receptors in schizo phrenia and that patients with this illness have an in· creased release and metabolism of NE.
Our fIndings of no diff erence in urinary HV A, with or without DBQ, in patients versus control subjects does suggest that the increased plasma HV A concentrations in plasma of schizophrenics reported here and in numerous other studies may not mean that there is in· creased synthesis of DA by whole-brain in schizophrenic patients. Comments about this disparity are as follows.
The gas chromatography-mass spectrometry method has a coefficient of variation of 5% and in other work has been accurate enough to detect differences in plasma HV A of 0.2 ng (approximately 5000 times this concentration is found in urine). Thus, problems with analytic methods are probably not an explanation. In nonhuman primates, almost all (about 95%) HV A is ex· creted into urine and HV A gives a good overall mea· sure of DA synthesis (Miller et al. 1987) . It seems likely that in humans, routes of HV A excretion other than urine are not important. If the half-life of HV A we re very long, it might mean that urinary values of HV A would more closely reflect past rather than present con· centrations of plasma HV A. This does not appear to be the case, however, as the half life of HV A is reported to be about 1 hour (Elchisak et a1. 1979; Anggard et al. 1974) . Alternatively, the patients may not have been at a steady state or were different from the control sub jects in terms of diurnal variation of HV A. However, our finding of a strong time effect during the placebo challenge for both patients and controls argues against this possibility. We also found no differences between patients and control subjects in renal clearance of plasma HV A. The sample size from which the clear ance data were calculated is relatively small and this part of our work should be repeated. Unfortunately, values for both urine and plasma were collected on a small er number of individuals than the total studied. Finall y, these fIndings with urinary and plasma HV A might be secondary to diff erences between patients and control subjects with the patients having a metabolic shunt to DOPAC in the kidney. The DOP AC data as given in Table 3 , however, do not support this possi bility .
The fInding of no apparent difference in the syn thesis of DA between patients and controls, as reflected in urinary HV A, is consistent with the many studies that ha ve reported no differences in CSF HV A between patients and control subjects (Berger et al. 1980; Bowers 1973; Bowers et al. 1969; Winblad et al. 1979; Nyback eta!. 1983; Persson and Roos 1969; Rimon et al. 1971 ). This is not to say that differences between patients and control subjects in DA system function are not pres ent, but rather to suggest that the difference is not in tota! overall synthesis. There could be differences in the patterns of impulse flow in DA systems. For example, bursts of DA neuronal fIring occurring as 100 pulses in a short period might not be diff erent in terms of HV A production from a steady monotonic ftring of 100 pulses occurring over a longer period, but the functional SignifIcance could be quite large. Alternatively, differ ent DA systems could have opposite changes in activ ity, leading to no detectable overall change in HV A out put (Davis et aI. 1991) . Moreover, small changes in one system might be diluted out when overall brain syn thesis is measured. A recent study does indicate that most HV A from human brain is from subcortical struc tures (Lambert et al. 1991) .
One important caveat should be noted. When the study began we attempted to study 24-hour urine spec imens from patients. Because of difft culties around diet, activity, and completeness of collection these collections proved not to be reliable or useful. Later in the study we switched to the 3.5-hour collections, with satisfac tory results. This meant, however, that we were able to obtain results on urine only in a subset of patients (n = 10). Given the standard deviation of urinary HV A determinations and setting (l at 0.05, a power analysis indicates that with this number of patients the efficiency isonJ y about 65%. Thus, it seems possible that if a larger number of patients had been studied, a signiftcant diff erence in urinary HV A between patients and con trol subjects might have been found. Initially, our patients were not taking any medica tion for 1 week and then were receiving DBQ for an other 7 to 14 days and were off psychotropic medica tion during this time. Thus they received a minimal neuroleptic washout of 2 weeks. Observations by other Catecholamine Metabolism in Schizophrenia 105 groups of investigators suggest that this 2 week washout period may be satisfactory. For example, Bun ney and Grace (1978) found that DA cells in the rat dien cephalon were in depolarization block after chronic ad ministration of neuroleptics but began to fIre normally after 2 weeks without medication. Studies with PET scans that were recently reported indicate that the brain is cleared of all neuroleptics within 10 to 12 days after patients cease taking medication (Farde et al. 1988 ). However, Pickar et al. (1984 Pickar et al. ( , 1986 reported that plasma HV A values increased at the 5th week of washout. If this pattern had been obtained in our study it would mean that our schizophrenic patients would have had even higher values than those reported here and our fIndings of signiftcant differences for HV A and MHPG might have been amplifted if we had used a longer washout time. Most of our patients were very sick, agi tated, and aroused at the time biologic samples were obtained. Other authors (Bowers 1978; Ashcroft et al. 1966 ) have commented upon the elevated CSF HV A values that are seen with psychotic patients. For exam ple, Bowers (1978) noted that the more acute the onset, the more disturbed the patient, and the greater the psy chosis, the higher the level of CSF HV A. In an initial report on this problem, Ashcroft et al. (1966) also noted that patients who were more excited were those who had the higher CSF HV A levels. The results of our behavioral-chemical analyses support the possibility that we had higher plasma metabolite values because our patients were quite ill and psychotic. The lack of any signiftcant correlation of the anxiety-agitation fac tor on the BPRS with any biochemical measure does not support the suggestion (Ashcroft et al. 1966 ) that these relationships were due solely to increased anxiety agitation. However, activity in patients is difftcult to quantitate and it cannot be ruled out that an activity variable may have accounted at least in part for our fIndings.
Earlier published work indicated that for the NE metabolite MHPG about one-half of the MHPG in urine was derived from the CNS. However, subsequent work indicates that MHPG is partially converted to VMA and, in contrast to HV A, crosses the blood-brain barrier to the CSF with relative ease (Kopin et al. 1983; Pletscher et al. 1967; Guldberg and Yates 1968) . Therefore, the earlier estimate of the CNS contribution of MHPG to plasma and urine has been revised downward to about one-third and correlations between CSF and plasma are not taken as indicating that a signiftcant amount of plasma MHPG is derived from the CNS. This fact, along with other problems noted next, tends to confound the interpretation of MHPG data that are obtained in pa tients who are receiving DBQ. There seems to be little question that the administration of DBQ results in a decrement of MHPG in plasma, CSF, and urine (Maas et al. 1988; Swann et al. 1980; Riddle et al. 1986 ), but the degree to which this decrease is of central origin remains open to question. In the report by Maas et al. (1979a) it was found that DBQ administration resulted in a decrement of MHPG production by brain. This was somewhat surprising since DBQ does not cross the blood-brain barrier and in these same experiments DBQ did not produce a change in the CNS production of HV A. Also in a previous paper (Maas et al. 1988) , we found that DBQ administration was associated with a 2.8 ng/ml fall in plasma and a 5 ng/ml fall in CSF, i.e., the fall in CSF MHPG alone was too great to be ac counted for solely by the fall in plasma MHPG. There fore the more conservative interpretation would be that the reduction in MHPG in CSF, plasma, and urine is probably due to a peripheral inhibition of MAO as well as some indirect action of DBQ on the brain. For exam ple, DBQ is an antihypertensive drug and it may be that by initiating changes in the peripheral NE system there are also compensatory changes in CNS NE activity. In unpublished experiments (G Aghajanian and JW Maas) we have found that acute treatment of rats with DBQ does not alter locus coeruleus (LC) unit recordings but we do not have data regarding the effects on frr ing rates of the LC when DBQ is given chronically. We have also found, but not published (A Swann et al.) , that adminis tration of DBQ to rats produces a small fall in brain MHPG but that the brain's concentration of MHPG has returned to normal by 24 hours.
The present results, taken in conjunction with the preclinical and clinical research work, lead us to hypo thesize that alterations in both DA and NE brain sys tems are associated with schizophrenia/psychosis. This could occur because the systems are linked, i.e., there is evidence that NE system function may regulate some parts of the DA systems (Grenhoff and Svensson 1989) . Alternatively, these two systems may be involved in producing different facets of the schizophrenic illness, i.e., the DA system is involved with positive but not negative symptoms whereas NE systems are related to both positive and negative symptoms.
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